Lexaria Bioscience CEO outlines 2025 progress and 2026 plans
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Lexaria Releases Annual Letter from the CEO
January 12, 2026 9:10 AM ESTKELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq: LEXX)(Nasdaq: LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders.
CEO Letter to Stakeholders
Dear Fellow Stakeholders,
I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year... More
